Evidence map›Paper›PMID 42000813›Full record

ArticleScientific reports2026

Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurements.

Marissa F Farinas, Yijun Chen, Xuemei Zeng, Michel N Nafash, Ann D Cohen, Oscar L Lopez, Thomas K Karikari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marissa F FarinasDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Yijun ChenDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Xuemei ZengDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Michel N NafashDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Ann D CohenDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Oscar L LopezDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Thomas K KarikariDepartment of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA. Karikaritk@upmc.edu.

Funding

Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5M
Alzheimer Diagnosis in older Adults with Chronic Conditions ADACC NetworkU24AG082930 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicole R. Fowler, Thomas K Karikari · 2023 to 2026
$7.3M
NIA NIH HHS R01 AG083874NIA NIH HHS U24 AG082930
6 · The paper itself

Abstract

The NULISAseq CNS Disease Panel has high potential for AD diagnosis, but the comparability of serum vs. plasma remains unclear. We compared its performance on 43 matched serum-plasma pairs from a memory clinic cohort. The panel reproducibly quantified 124 targets (mean CV = 4.9%) with high detectability (mean = 95.7%). Serum-plasma correlations were strong (ρ > 0.7) for 79 targets. 48 targets had significant NULISA Protein Quantification (NPQ) differences, with 32 higher in plasma. Plasma had more erythrocyte-enriched proteins (HBA1, PGK1, SOD1, PRDX6), while serum had more platelet-derived proteins (CD40LG, BDNF, VEGFA, Aβ40). For classical AD biomarkers, serum-plasma correlations were stronger for p-tau, GFAP, and NfL (ρ > 0.9) than for Aβ targets (ρ = 0.594–0.785). Tau levels were higher in plasma; GFAP and NfL were similar, and Aβ peptides were mixed. Twelve targets, along with p-tau217/Aβ42, were linked to AD diagnosis, with plasma generally showing stronger effects. Our results support serum use but suggest plasma performs better for AD using this panel.

Indexed as

Alzheimer DiseaseBiomarkersPlasmaProteomicsSerumAgedAmyloid beta-PeptidesFemaleGlial Fibrillary Acidic ProteinHumansMaletau ProteinsAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic Proteintau ProteinsAlzheimer’s diseaseBlood-based biomarkersNULISASeq™ CNS disease panelSerum vs plasma

Identifiers

PMID42000813
PMCPMC13254288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.